Cargando…

SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines

SARS-CoV2 is a member of human coronaviruses and is the causative agent of the present pandemic COVID-19 virus. In order to control COVID-19, studies on viral structure and mechanism of infectivity and pathogenicity are sorely needed. The spike (S) protein is comprised of S1 & S2 subunits. These...

Descripción completa

Detalles Bibliográficos
Autores principales: Velusamy, Palaniyandi, Kiruba, Kannan, Su, Chia-Hung, Arun, Viswanathan, Anbu, Periasamy, Gopinath, Subash C.B., Vaseeharan, Baskaralingam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. on behalf of King Saud University. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523302/
https://www.ncbi.nlm.nih.gov/pubmed/34690467
http://dx.doi.org/10.1016/j.jksus.2021.101648
_version_ 1784585272858509312
author Velusamy, Palaniyandi
Kiruba, Kannan
Su, Chia-Hung
Arun, Viswanathan
Anbu, Periasamy
Gopinath, Subash C.B.
Vaseeharan, Baskaralingam
author_facet Velusamy, Palaniyandi
Kiruba, Kannan
Su, Chia-Hung
Arun, Viswanathan
Anbu, Periasamy
Gopinath, Subash C.B.
Vaseeharan, Baskaralingam
author_sort Velusamy, Palaniyandi
collection PubMed
description SARS-CoV2 is a member of human coronaviruses and is the causative agent of the present pandemic COVID-19 virus. In order to control COVID-19, studies on viral structure and mechanism of infectivity and pathogenicity are sorely needed. The spike (S) protein is comprised of S1 & S2 subunits. These spike protein subunits enable viral attachment by binding to the host cell via ACE-2 (angiotensin converting enzyme-2) receptor, thus facilitating the infection. During viral entry, one of the key steps is the cleavage of the S1-S2 spike protein subunits via surface TMPRSS2 (transmembrane protease serine 2) and results in viral infection. Hence, the S-protein is critical for the viral attachment and penetration into the host. The rapid advancement of our knowledge on the structural and functional aspects of the spike protein could lead to development of numerous candidate vaccines against SARS-CoV2. Here the authors discuss about the structure of spike protein and explore its related functions. Our aim is to provide a better understanding that may aid in fighting against CoVID-19 and its treatment.
format Online
Article
Text
id pubmed-8523302
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier B.V. on behalf of King Saud University.
record_format MEDLINE/PubMed
spelling pubmed-85233022021-10-20 SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines Velusamy, Palaniyandi Kiruba, Kannan Su, Chia-Hung Arun, Viswanathan Anbu, Periasamy Gopinath, Subash C.B. Vaseeharan, Baskaralingam J King Saud Univ Sci Review SARS-CoV2 is a member of human coronaviruses and is the causative agent of the present pandemic COVID-19 virus. In order to control COVID-19, studies on viral structure and mechanism of infectivity and pathogenicity are sorely needed. The spike (S) protein is comprised of S1 & S2 subunits. These spike protein subunits enable viral attachment by binding to the host cell via ACE-2 (angiotensin converting enzyme-2) receptor, thus facilitating the infection. During viral entry, one of the key steps is the cleavage of the S1-S2 spike protein subunits via surface TMPRSS2 (transmembrane protease serine 2) and results in viral infection. Hence, the S-protein is critical for the viral attachment and penetration into the host. The rapid advancement of our knowledge on the structural and functional aspects of the spike protein could lead to development of numerous candidate vaccines against SARS-CoV2. Here the authors discuss about the structure of spike protein and explore its related functions. Our aim is to provide a better understanding that may aid in fighting against CoVID-19 and its treatment. The Authors. Published by Elsevier B.V. on behalf of King Saud University. 2021-12 2021-10-19 /pmc/articles/PMC8523302/ /pubmed/34690467 http://dx.doi.org/10.1016/j.jksus.2021.101648 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Velusamy, Palaniyandi
Kiruba, Kannan
Su, Chia-Hung
Arun, Viswanathan
Anbu, Periasamy
Gopinath, Subash C.B.
Vaseeharan, Baskaralingam
SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines
title SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines
title_full SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines
title_fullStr SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines
title_full_unstemmed SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines
title_short SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines
title_sort sars-cov-2 spike protein: site-specific breakpoints for the development of covid-19 vaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523302/
https://www.ncbi.nlm.nih.gov/pubmed/34690467
http://dx.doi.org/10.1016/j.jksus.2021.101648
work_keys_str_mv AT velusamypalaniyandi sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines
AT kirubakannan sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines
AT suchiahung sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines
AT arunviswanathan sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines
AT anbuperiasamy sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines
AT gopinathsubashcb sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines
AT vaseeharanbaskaralingam sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines